Quibim secures $50m Series A to fuel AI-powered medical imaging solutions for better disease detection

We are excited to share the news that Adara portfolio company Quibim, a leading digital health tech company pioneering the use of imaging biomarkers for precision medicine, has closed $50 million in a Series A investment round led by Asabys. 

Adara Ventures participated in the round alongside Buenavista partners, UI Investissements, Go Hub, Amadeus Capital Partners, APEX Ventures, Partech, Leadwind, and individual investors, including Tony Fadell (Principal at Build Collective, Founder of Nest, and inventor of the iPod), and Dr. Jonathan Milner, Founder of Abcam plc.  

This new funding will enable Quibim to broaden its product pipeline and accelerate its global commercial growth.

AI and digital twin imaging technologies: The future of personalized medicine

Quibim is on a bold mission to understand every tissue point in the human body, non-invasively and in real time. To make this vision a reality, the company creates foundational AI models for medical imaging, extracting meaningful insights from MRI, CT, and PET scans.

These insights allow for precise phenotype characterization and outcome prediction, driving breakthroughs in fields like oncology, immunology, and metabolic disorders.

This technology paves the way for developing human digital twins—sophisticated, dynamic models that go beyond traditional health monitoring and can enable better patient stratification, increase the success of drug development programs, and allow treatments to be tested virtually before being applied in real life.

Today, the company is building digital twins at the organ and lesion level, exemplified by solutions like QP-Brain, QP-Prostate, and QP-Liver. As the volume of whole-body scans and imaging data continues to rise, Quibim’s models are poised to analyze the human body in its entirety. 

With a vision to transform healthcare, the company is seamlessly integrating advanced imaging, computing, and AI to drive this groundbreaking shift forward.

Analyzing patients in 170+ institutions globally & counting

Founded in 2012 and spun out of La Fe Health Research Institute in Valencia, Spain, Quibim has achieved extraordinary growth in the number of patients analyzed by its solutions. 

We first partnered with Dr. Angel Alberich-Bayarri and the Quibim team in 2020. The company has since experienced remarkable growth in the number of patients analyzed by its products, particularly over the past year, driven by the regulatory approval of its solutions at the end of 2023.

Quibim now boasts over 170 installations globally, partnering with renowned institutions such as Mass General Brigham and Stanford. With regulatory approvals spanning the US, EU, UK, and beyond, Quibim continues to expand its reach and impact.

Last year, Philips announced a global partnership with Quibim to integrate its AI models into MR scanners, while the company also secured strategic alliances with leading biopharma giants such as Merck KGaA and Novartis.

FDA clearance and doubling down on US expansion

After success in Europe, Quibim is now expanding further into the US. With FDA-cleared solutions, the company aims to help more US healthcare providers and clinical researchers process large volumes of data from medical scans.

“Quibim’s mission is to turn imaging into a catalyst for precision health, and we are deeply grateful to both our new and current investors for their support,” said Dr. Ángel Alberich-Bayarri, CEO and co-founder of Quibim.

“Our global expansion into the US is a critical milestone as we work with pharmaceutical leaders and healthcare providers to unlock the power of imaging to revolutionize diagnostics and improve patient outcomes.”

The Adara view: Delivering breakthrough solutions for disease detection and diagnosis

Quibim is at the forefront of imaging biomarkers research in life sciences, driving the development of advanced algorithms that can transform imaging data into actionable predictions in oncology, immunology, and neurology. We believe Quibim’s AI-powered imaging solutions will help pharmaceutical companies around the world improve clinical trials significantly and speed up drug development through more accurate insights.

We are pleased to invest further in our partnership with Quibim as they continue growing and developing breakthrough solutions to address the most critical challenges in disease detection and diagnosis.

Learn more about Quibim on our blog here and in the press release here.